| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Ovarian cancer | Phase 2 | Intravenous | Oncology | |
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Post-transplant lymphoproliferative disorder | Phase 2 | Intravenous | Oncology | |
| Aldeyra Therapeutics Inc. | Reproxalap (ADX-102) - (TRANQUILITY-2) | Dry eye disease | Phase 3 | Ocular | Opthalmic | |
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Post-transplant lymphoproliferative disorder | Phase 2 | Intravenous | Oncology | |
| Aldeyra Therapeutics Inc. | ADX-629 | Moderate / Acute Alcoholic Hepatitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Aldeyra Therapeutics Inc. | Reproxalap (ADX-102) | Sjögren-Larsson Syndrome (SLS) | Phase 3 | Ophthalmic | Genetic Disorder | |
| Aldeyra Therapeutics Inc. | Reproxalap - (Crossover study) | Dry eye disease | Phase 3 | Ophthalmic | Opthalmic | |
| Aldeyra Therapeutics Inc. | Reproxalap (ADX-102) - (INVIGORATE-2) | Allergic conjunctivitis | NDA Filing | Data Released | Ophthalmic | Opthalmic |